Vorapaxar: a novel protease-activated receptor-1 inhibitor.
about
G-protein-coupled receptors signaling pathways in new antiplatelet drug developmentCurrent antiplatelet treatment strategy in patients with diabetes mellitus.Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis.Pharmacology of antiplatelet agents.Vorapaxar: first global approval.Vorapaxar in the secondary prevention of atherothrombosis.
P2860
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@en
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@nl
type
label
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@en
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@nl
prefLabel
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@en
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@nl
P2093
P2860
P1476
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
@en
P2093
Paul A Gurbel
Udaya S Tantry
Young-Hoon Jeong
P2860
P304
P356
10.1517/13543784.2011.606809
P407
P577
2011-08-06T00:00:00Z